Niva Bupa retail health growth and claims improvement drive Q1 FY27 PAT beat

Investment View and Valuation

Motilal Oswal Financial Services Limited retains its Buy recommendation on Niva Bupa following a strong 1QFY27 operating performance and a significant PAT beat. The broker believes Niva Bupa is well positioned to capture the health-insurance growth opportunity, supported by its strategic global partner, expanding customer base, diversified distribution channels and innovative product offerings.

The broker attributes the company’s industry-leading growth to the GST exemption on retail health insurance and its multi-channel distribution strategy. A greater share of fresh retail business and a lower group-health mix are helping reduce loss ratios, while operational efficiency is improving expense-of-management ratios.

Motilal Oswal values Niva Bupa at 30 times FY28E IFRS PAT to derive a target price of Rs 103.

1QFY27 Financial Performance

Claims increased 21% year on year to Rs 1,433 crore, in line with estimates. The claims ratio improved by 380 basis points year on year to 63.5%, better than Motilal Oswal’s expectation of 68%. The retail claims ratio improved 90 basis points year on year to 67.5%.

Operating expenses rose 24% year on year to Rs 690 crore, 5% above estimate. The operating-expense ratio was 37.2%, compared with 36.4% a year earlier. Expense of management stood at 35.2%, approaching the regulatory threshold of 35%. The retail health indemnity renewal rate improved to 95.8% from 92.5%.

Retail Health Growth and Distribution

Retail health accounted for approximately 75% of business in 1QFY27, while the group-health contribution declined to 24% amid a competitive group-health pricing environment. Management stated that retail health market share increased to 11.1%. Retail health premium grew 46.5% year on year, while fresh retail business increased 41%.

Management aims to sustain a retail-health growth alpha of 8–10% over the industry, supported by multi-channel distribution, deeper penetration in Tier-2 and Tier-3 markets and product innovation. July 2026 trends remained strong. Seasonal infections are expected over the coming months, although management said that no abnormal claims trends had emerged.

Claims, Efficiency and Return Outlook

Management attributed the improvement in the loss ratio to a shift away from large corporate group accounts towards affinity groups and SME business, along with stronger fresh retail business. The Preferred Provider Network can reduce claim severity by 15–20% through more efficient hospital routing and reduced fraud.

• Retail renewal loss ratio was approximately 75%.
• Annual price increases are in the high single digits.
• Operating expenses remain below 20%.
• Other operating expenses are expected to normalise from 3QFY27.
• The impact from the loss of input tax credit has been passed on to distributors.

Management targets a mid-to-high-teen RoE by FY29, compared with a trailing four-quarter RoE of 11.8%.

Investment Assets and Operating Network

At the end of 1QFY27, Niva Bupa had investment assets of Rs 10,000 crore, an investment yield of 7.2% and a solvency ratio of 2.25 times. Average ticket size per policy increased to Rs 30,224 from Rs 24,889. Policies with more than Rs 10 lakh of sum insured contributed 92.7% of gross written premium, compared with 81.7% a year earlier.

• Hospital network: 10,668 hospitals.
• Preferred partner network: 1,133 partners.
• Agents added during the quarter: 13,000.
• Total agent base: 251,834.
• Banca partnerships added during the quarter: 13.
• Total banca partnerships: 134.

The board approved raising up to Rs 500 crore through debt instruments, principally to refinance a Rs 250 crore non-convertible debenture with a call option due in 2026 and to support growth.

Forecasts and Accounting Transition

Niva Bupa transitioned to Ind AS accounting in 1QFY27, and Motilal Oswal prepared its estimates accordingly.

Key Monitorables

• Sustaining retail-health growth ahead of the industry, particularly through Tier-2 and Tier-3 expansion.
• Further improvement in claims and loss ratios as the business mix shifts towards fresh retail, affinity groups and SMEs.
• Normalisation of other operating expenses from 3QFY27.
• Seasonal infection trends and any associated impact on claims.
• Progress towards the mid-to-high-teen RoE target by FY29.